TISIDB

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00443 Ubiquitin carboxyl-terminal hydrolase PF02148 Zn-finger in ubiquitin-hydrolases and other protein
Function	Specifically deubiquitinates 'Lys-120' of histone H2A (H2AK119Ub), a specific tag for epigenetic transcriptional repression, thereby acting as a coactivator. Deubiquitination of histone H2A is a prerequisite for subsequent phosphorylation at 'Ser-11' of histone H3 (H3S10ph), and is required for chromosome segregation when cells enter into mitosis. In resting B- and T-lymphocytes, phosphorylation by AURKB leads to enhance its activity, thereby maintaining transcription in resting lymphocytes. Regulates Hox gene expression via histone H2A deubiquitination. Prefers nucleosomal substrates. Does not deubiquitinate histone H2B.

> Gene Ontology [ TOP ]
Biological Process	GO:0006414 translational elongation GO:0006417 regulation of translation GO:0006448 regulation of translational elongation GO:0007067 mitotic nuclear division GO:0010608 posttranscriptional regulation of gene expression GO:0016570 histone modification GO:0016578 histone deubiquitination GO:0016579 protein deubiquitination GO:0034248 regulation of cellular amide metabolic process GO:0034250 positive regulation of cellular amide metabolic process GO:0035520 monoubiquitinated protein deubiquitination GO:0035521 monoubiquitinated histone deubiquitination GO:0035522 monoubiquitinated histone H2A deubiquitination GO:0045727 positive regulation of translation GO:0045901 positive regulation of translational elongation GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051262 protein tetramerization GO:0051289 protein homotetramerization GO:0070536 protein K63-linked deubiquitination GO:0070537 histone H2A K63-linked deubiquitination GO:0070646 protein modification by small protein removal
Molecular Function	GO:0003713 transcription coactivator activity GO:0004175 endopeptidase activity GO:0004197 cysteine-type endopeptidase activity GO:0004843 thiol-dependent ubiquitin-specific protease activity GO:0008234 cysteine-type peptidase activity GO:0019783 ubiquitin-like protein-specific protease activity GO:0032182 ubiquitin-like protein binding GO:0036459 thiol-dependent ubiquitinyl hydrolase activity GO:0042393 histone binding GO:0043130 ubiquitin binding GO:0101005 ubiquitinyl hydrolase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5688426: Deubiquitination R-HSA-392499: Metabolism of proteins R-HSA-597592: Post-translational protein modification R-HSA-5689880: Ub-specific processing proteases

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between USP16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of USP16 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of USP16 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.144	0.638
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.437	0.809
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.072	0.958
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.116	0.697
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.316	0.88
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.136	0.959
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.033	0.927
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.136	0.937
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.184	0.921
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.346	0.778
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.802	0.668
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.041	0.503

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of USP16 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of USP16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of USP16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by USP16. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of USP16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of USP16 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between USP16 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	USP16
Name	ubiquitin specific peptidase 16
Aliases	Ubp-M; ubiquitin specific protease 16; UBPM; deubiquitinating enzyme 16; ubiquitin thioesterase 16; ubiquiti ......
Chromosomal Location	21q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting USP16 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse USP16